IMA - NASDAQ

ImageneBio Inc

IMA·NASDAQ

$5.63

+1.3%

HealthcareBiotechnology

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

Statements Value Model

At a Glance

Live Snapshot

Market Cap$63.50M

EPS-10.7600

P/E Ratio-0.52

Earnings Date07/23/2026

152.98M

Assets

3Y-11.0%

5Y-9.0%

10Y+640.0%

19.84M

Total Liabilities

27%

3Y-22.0%

5Y-93.0%

10Y-70.0%

133.14M

Total Equity

3Y-9.0%

5Y-232.0%

10Y-390.0%

ImageneBio Inc Funding & Solvency Profile

IMA · NASDAQ

Current Assets

Cash & Cash Equivalents34.97M

Net Receivables1.30M

Inventory0.00

Other Current Assets63.21M

Total Current Assets140 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets12.69M

Total Non-Current Assets13 M

Total Assets

152.98M

Financial Health Analysis

Current Ratio

12.49x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.15x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

129 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

92% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

ImageneBio Inc Balance Sheet

IMA • NASDAQ

ImageneBio Inc Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	35M	39.4M	119.9M	59.9M	232.2M	162.5M	82.1M	18.2M
Short-Term Investments	40.8M	85M	55.6M	97M	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	75.8M	124.4M	175.5M	156.9M	232.2M	162.5M	82.1M	18.2M
Net Receivables	1.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	1.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	2M	2.1M	3.7M	1.9M	1.9M	1.2M
Other Current Assets	63.2M	2.8M	1.2M	964K	629K	1.5M	1.3M	582K
Total Current Assets	140.3M	127.2M	178.7M	160M	236.5M	166M	85.2M	20M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	0.0	4.2M	8M	8.5M	9M	1.6M	769K	696K
Other Non-Current Assets	12.7M	10.1M	5.4M	3.8M	2.4M	872K	0.0	0.0
Total Non-Current Assets	12.7M	14.3M	13.4M	12.2M	11.4M	2.4M	769K	696K
Total Assets	153M	141.5M	192.1M	172.3M	247.9M	168.4M	86M	20.7M
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.4M	897K	2.1M	2.1M	2.4M	2.1M	935K	2.3M
Accounts Payable	1.4M	897K	2.1M	2.1M	2.4M	2.1M	935K	2.3M
Accrued Expenses	0.0	4.3M	5.2M	3.2M	3M	3.2M	2.6M	1.4M
Capital Lease Obligations (Current)	2.3M	3.8M	3.6M	1.9M	1.9M	186K	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	9.2M	17.1M	20.6M	20.7M	126K
Other Current Liabilities	7.5M	1.8M	3.4M	5.1M	2.8M	2.2M	121K	126K
Total Current Liabilities	11.2M	10.8M	14.2M	21.5M	27.2M	28.3M	24.3M	3.8M
NON-CURRENT LIABILITIES
Long Term Debt	7M	0.0	0.0	0.0	0.0	0.0	78.9M	62.6M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	7.7M	35.1M	44.3M	116K
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	-78.9M	0.0
Other Non-Current Liabilities	870K	1.1M	950K	0.0	0.0	206M	0.0	0.0
Total Non-Current Liabilities	8.6M	4.8M	8.1M	3.8M	12.8M	241.1M	123.1M	62.7M
Capital Lease Obligations	3M	7.5M	10.7M	5.7M	7M	186K	0.0	0.0
Total Liabilities	19.8M	15.6M	22.3M	25.3M	40M	269.5M	147.4M	66.5M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.4M
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	78.9M	62.6M
Common Stock	11K	48K	48K	36K	36K	3K	3K	19K
Additional Paid-In Capital	363.1M	457.4M	452.1M	361.9M	353.3M	10.3M	5.6M	4.4M
Retained Earnings	-230.1M	-331.6M	-282.4M	-214.2M	-145.5M	-111.3M	-67.1M	-50.3M
Accumulated Other Comprehensive Income/Loss	87K	68K	-48K	-763K	0.0	0.0	-78.9M	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	78.9M	-58.2M
Total Stockholders' Equity	133.1M	125.9M	169.8M	147M	207.9M	-101M	17.4M	-45.8M
Total Equity	133.1M	125.9M	169.8M	147M	207.9M	-101M	-61.5M	-45.8M
SUMMARY
Total Liabilities & Equity	153M	141.5M	192.1M	172.3M	247.9M	168.4M	86M	20.7M
Total Investments	40.8M	85M	55.6M	97M	0.0	0.0	0.0	0.0
Total Debt	10M	7.5M	10.7M	5.7M	7M	186K	78.9M	62.6M
Net Debt	-25M	-31.9M	-109.2M	-54.2M	-225.2M	-162.3M	-3.2M	44.4M
Shares Outstanding	11,181,676	11,181,676	11,181,676	11,181,676	11,181,676	11,181,676	11,181,676	11,181,676

SEC Filings

IMA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 30, 2026	June 16, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 13, 2026	April 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 17, 2026	March 12, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 10, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 10, 2026	March 10, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 17, 2026	February 12, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 18, 2025	December 12, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 19, 2025	November 19, 2025	2025	View Filing

Showing 1 to 10 of 87 filings

Related Guides

Blog Categories

Continue your IMA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.